Senseonics Touts Solid Data for 180 Day CGM | 合法醫療器材資訊網

2021年6月4日—Eversense,whichisconsideredadirectcompetitortoDexCom'sCGMsystems,firstwonanodfromFDAin2018.Senseonicsfiledtoget ...

Senseonics strutted out some promising results from a clinical study of its Eversense system, a 180-day continuous glucose monitor sensor.

The Germantown, MD-based company showed off data from the PROMISE study during an oral presentation at the 14th Annual International Conference on Advanced Technologies and Treatments of Diabetes Meeting. The company said results were presented for both the primary sensor and for a secondary sensor with modified chemistry referred to as the SBA sensor.

In the study 181 patients at eight sites across the U.S. had a primary sensor inserted subcutaneously in their left upper arm; 43 of these partici...